Search...
Why Cellectis Stock Is Trading Higher Today
I'm PortAI, I can summarize articles.
Cellectis A/S announced a breakthrough in gene therapy using circular single-stranded DNA (CssDNA) for efficient gene insertion in hematopoietic stem and progenitor cells (HSPCs). This advancement, utilizing TALEN technology, enhances non-viral gene therapy potential. CssDNA showed higher efficiency and applicability across cell types, marking a pivotal step in cell and gene therapies. Consequently, Cellectis' stock rose by 8.27% to $4.45. The company has $225 million in cash reserves, sufficient to fund operations until the second half of 2027.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments